The European Commission has agreed in principle to grant an additional six months extension to the project. This will effectively bring the project end date to 31 December 2021.
While both ChiLTERN and RELIVE are working with the aim to cure children with liver cancer, RELIVE is specific in that it is developing the first registry of its kind for children with a relapsed or refractory Liver cancer.
RELIVE was created in association with researchers from Australia, Canada, Europe, Japan, New Zealand and the USA and will look at past cases and recent developments, examining treatments and their outcomes. It will also document data prior to and post treatment, track the progress and document the outcome at the end of treatment in order to identify the best way forward for future patients. RELIVE would be happy to hear from parents or patients who have suffered from a RELAPSE in Liver Cancer who would like to share their story with others who may be in a similar situation.